Viron is a private company pioneering the development of viral protein therapeutics to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. This approach provides enormous competitive advantages to Viron by providing numerous unique product development opportunities. Viron's pipeline of compounds, across all stages of development, combined with a robust discovery program and strong intellectual property positions the Company to be a leader in the discovery and commercialization of bio-therapeutics to treat inflammatory-based diseases.
Viron secured a $20M Series A round of financing in 2006 with a dedicated group of international investors including:
Amgen Ventures
|
Novartis Pharma AG
|
GrowthWorks Capital
|
BDC Venture Capital
|
Fairway Capital
|
Trudell Medical Ltd.
|
That investment enabled the Company to achieve a number of significant development milestones, including the completion of a Phase IIa clinical trial, the IND preparation for a second indication with its lead candidate, the advancement of its next clinical candidate, a potent TNF-α inhibitor, and the scale up and optimization of its manufacturing process to prepare for market launch and further reduce cost of goods. Viron continues to exploit its PROSPECTTM discovery process to identify and prioritize new candidates to sustain its platform.
Inquiries
Should you be interested in discussing investment opportunities, please contact:
James M. Rae
President & CEO
By Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
By Mail:
Viron Therapeutics Inc.
700 Collip Circle, Suite 203
London, ON Canada
N6G 4X8
By Telephone: 519.858.5109
By FAX: 519.858.5103
